What is the last grey market premium of Accretion Pharmacueticals IPO?

 Click

Listing Review: Will update on listing.

Subscription status of Accrtion Pharmacueticals IPO

Accretion Pharmacueticals IPO
(Day 1)

Price Rs. 101 Lot 1200 shares, Rs. 33.99 Crore

QIB NII x RII x Total x Applications
         
Note: .

Accretion Pharmacueticals Allotment Link: 

 

 

What is the business of Accretion Pharmacueticals?

About Accretion Pharmaceuticals Limited

Established in 2012, Accretion Pharmaceuticals Limited is a diversified pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare products, including tablets, capsules, and various specialty formulations. The company also provides contract manufacturing services to meet the diverse needs of its partners.

Manufacturing Capabilities

Accretion’s state-of-the-art manufacturing facility is located in Sanand, Ahmedabad (Gujarat), and is equipped to produce a variety of pharmaceutical dosage forms, including:

  • Tablets and Capsules – Covering therapeutic categories such as antibiotics, anti-inflammatory agents, pain management, cardiovascular, and gastrointestinal treatments.
  • Oral Liquids and Syrups – Designed for respiratory care, pediatric use, and digestive health.
  • External Preparations – Including ointments, creams, gels, lotions, medicated shampoos, mouthwashes, and dusting powders for skin and hair care.
  • Oral Powders – Such as sachets and dry syrups.
  • Ayurvedic and Herbal Products – Promoting holistic health with natural remedies for immunity, digestion, and overall well-being.

Certifications and Quality Standards

The company is ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certified, demonstrating a strong commitment to quality assurance, environmental sustainability, and food safety management.

Global Presence

Accretion Pharmaceuticals has extended its reach to over 20 countries across Africa, Southeast Asia, and the Middle East, continually expanding its international footprint.

Workforce

As of January 2025, the company employs 83 professionals, including 4 Executive Directors, supporting its operations and growth.

Get more information about the company @ https://accretionpharma.com/

Accretion Pharmacueticals IPO Details

IPO opens on  14 May 2025
IPO closes on  16 May 2025
Issue Type Book Built Issue IPO
Issue Size 2946000 Shares /
Rs 29.75 Crore
* Fresh Issue 2946000 Shares /
Rs 29.75 Crore
* Offer for Sale – – shares /
Rs.- crore
Market Maker Portion 147600 Shares
Net offer to Public 2798400 Shares/
Rs 28.26 Crore
Face Value per share Rs. 10
Price Band Rs. 101
Employee discount  Rs. 0 per share
Retail Lot Size  1200 Shares
Listing will at  NSE SME

Shares offered in IPO

  Shares Rs. (Crore)
QIB (50%) 1399200 14.13
HNI (15%)   419760   4.24
RII  (35%)   979440   9.89
Total Shares  2798400 28.26
Retail portion will be
oversubscribed by 
816
Forms
How much Shares to Apply in this IPO?
Min Retail Application 1200 Shares Rs.121200
Min HNI Application  2400 Shares Rs. 242400

Who are the Promoters of Accretion Pharmacueticals?

The promoters of the company are Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel and Mr. Hardik Mukundbhai Prajapati.

What are the Objects of Accretion Pharmacueticals IPO?

The Company proposes to utilize the Net Proceeds towards funding of the following objects:
a) Capital expenditure towards purchase of new equipment/ machineries, etc.
b) Capital expenditure towards upgradation of existing manufacturing facility
c) Repayment/prepayment of certain borrowings availed by the Company
d) Funding working capital requirements
e) General Corporate Purpose

Tentative timetable

IPO opens on 14 May 2025
IPO Closes on 16 May 2025
IPO Allotment on  19 May 2025
Refund Initiation  20 May 2025
Credit of Shares 20 May 2025
Listing on 21 May 2025
Registered Office of the Company
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand, Gujarat
The Lead Manager of this IPO
Jawa Capital Services Pvt Ltd

Who is the Registrar to IPO?

Kfin Technologies Ltd

Accretion Pharmacueticals IPO GMP grey market premium, review, Subscription, allotment, listing estimate

Accretion Pharmacueticals Financials
Period Ended 31-Dec-24 31-Mar-24 31-Mar-23 31-Mar-22
Assets 39.99 27.05 20.58 17.74
Revenue 35.75 33.94 29.53 22.58
Profit After Tax 5.24 3.88 0.1 0.08
Net Worth 13.58 5.35 3.84 3.08
Reserves and Surplus 5.41 1.35 0 0
Total Borrowing 13.79 13.48 8.47 7.61
Amount in ₹ Crore
Key Performance Indicators
KPI Values
ROE 72.47%
ROCE 36.73%
Debt/Equity 2.52
RoNW 72.47%
PAT Margin 11.51
Price to Book Value 7.55
EPS 4.74
PE Ratio 21.29

How Accretion Pharmacueticals IPO compares with the Peers?

Company Name P/E (x) RoNW (%)
Accretion Pharmaceuticals 11.56 38.54
Sakar Healthcare 48.89 4.45
Lincoln Pharma 12.3 15.74
Sotac Pharma 23.85 11.91

# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

Accretion Pharmacueticals IPO Review by Paresh Gordhandas, CA & Research Analyst.

Will update soon

+ from fundamental angle: 

+ from grey market angle: 

Quicklinks


 
Accretion Pharmacueticals IPO

 
Accretion Pharmacueticals IPO

Leave a Reply

Your email address will not be published. Required fields are marked *